• Explore /
  • Poster
  • / Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC).

Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Julie Graff

Julie Nicole Graff

VA Portland Health Care System, Portland and Knight Cancer Institute, Oregon Health & Science University, Portland, OR

Julie Nicole Graff , Heather H. Cheng , Jacqueline Vuky , Joshi J. Alumkal , Dustin Kreitner , Delia Petreaca , Petros Grivas , Michael Thomas Schweizer , Celestia S. Higano , Yiyi Chen , Evan Y. Yu , Tomasz M. Beer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02522715

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 86)

Abstract #

86

Poster Bd #

D10

Abstract Disclosures

Similar Posters

First Author: Joaquin Mateo

First Author: Antoine Angelergues

First Author: Mehmet Asim Bilen

First Author: Benedito A. Carneiro